Innate Biotherapeutics

Innate Biotherapeutics is a private, pre-clinical stage biotech leveraging a unique platform called mAbXcite, which conjugates beta-1,6-glucan to tumor-targeting antibodies. This approach aims to recruit and activate innate immune cells like neutrophils at the tumor site, initiating a cascade that primes a durable adaptive T-cell response, potentially treating a wide range of 'cold' tumors. The company is seeking strategic partnerships to advance its pipeline, which is positioned to work both as a monotherapy and in combination with established checkpoint inhibitors.

mAbXcite technology: A platform creating antibody-beta-1,6-glucan conjugates. The fungal carbohydrate beta-1,6-glucan is covalently linked to tumor-targeting monoclonal antibodies. This recruits endogenous antibodies, activates complement, and recruits/activates innate immune cells (neutrophils) to kill tumor cells and prime a subsequent adaptive T-cell response.

Innate Bio competes in the growing field of innate immune oncology, facing companies developing therapies targeting CD47, CD24, macrophage checkpoints, and other neutrophil-engaging platforms. Its differentiation lies in the specific use of a fungal carbohydrate to hijack a natural antibody-complement-neutrophil pathway. Success will depend on demonstrating superior efficacy or a better safety window compared to these alternative approaches.